Australian Nuclear Science and Technology Organization

What Australian Nuclear Science and Technology Organization does

ANSTO (Australian Nuclear Science and Technology Organisation) is an Australian Government statutory authority established in 1987 under the Australian Nuclear Science and Technology Organisation Act 1987, succeeding the Australian Atomic Energy Commission. It operates approximately $1.3 billion in specialized nuclear science infrastructure across two main campuses: Lucas Heights in Sydney (housing the OPAL multi-purpose reactor, Centre for Accelerator Science, National Deuteration Facility, nuclear medicine production facilities, and ANSTO Synroc operations) and Clayton in Melbourne (housing the Australian Synchrotron). The organization serves healthcare providers, academic researchers, mining and resources companies, and Australian Government agencies, with revenue generated through a combination of government statutory core funding and commercial activities including nuclear medicine production and export, fee-for-service research infrastructure access, analytical testing, radiation services, and minerals processing testwork.

ANSTO's technology portfolio centers on a national research infrastructure platform anchored by OPAL — a multi-purpose reactor using proliferation-resistant low-enriched uranium for medical radioisotope production, neutron scattering, and silicon irradiation — complemented by the Australian Synchrotron's multiple beamlines for crystallography, imaging, and spectroscopy. Proprietary technology assets include ANSTO Synroc for nuclear waste immobilization and CORIS360 gamma-neutron imaging systems based on compressed sensing. Approximately 1,200-1,500 highly-skilled staff support operations across materials science, health, climate science, mining, and engineering disciplines. ANSTO also holds the wholly-owned Australian Synchrotron subsidiary in Clayton.

The business model blends government statutory core funding with multiple commercial revenue streams: direct supply of radiopharmaceuticals and radiochemicals to Australian and international healthcare markets; fee-for-service beamtime and instrument access for academic and industrial researchers via dedicated user portals; commercial analytical services for resources sector clients; radiation safety training and instrument calibration; and emerging critical minerals processing services. ANSTO is currently positioning to commission Australia's first clay rare earth processing facility in 2026, backed by over $3 billion in Australia-US financing, with Australian Rare Earths' Koppamurra project designated as the primary user and additional metallurgical partnerships with Critica Limited and Chilwa Minerals. Strategic commercial emphasis is on therapeutic radioisotopes including Lu-177 and Ac-225, where the global nuclear medicine market is projected to grow from US$13.6 billion in 2026 to US$28.6 billion by 2033 at 11.2% CAGR.

Name

Australian Nuclear Science and Technology Organization

Legal name

Australian Nuclear Science and Technology Organisation

Website

https://ansto.gov.au

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ANSTO is Australia's Government statutory nuclear research organisation operating $1.3 billion of specialised infrastructure — including the OPAL reactor and Australian Synchrotron — serving healthcare, academic research, mining, and government clients through nuclear medicine production, research services, and analytical testing.

Ownership category

akta.pro rank

Product category

Nuclear Science Research and Infrastructure Services

NAICS

Scientific Research and Development Services (5417), Irradiation Apparatus Manufacturing (334517)

SIC

Services-Commercial Physical & Biological Research (8731), Hazardous Waste Management (4955)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Research & Test Reactor Operations (Non-Commercial Power) (EUACADAH), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Repository operations & waste emplacement (handling systems, emplacement, ventilation) (EUAKAGAI), Spent Fuel Management Engineering, Consulting & Digital Tools (Thermal/Shielding/Criticality, QA) (EUAKAHAL)

Keywords

• Nuclear medicine production
• Nuclear research services
• Synchrotron radiation research
• Radiation safety consulting
• Minerals processing services

Headquarters

HQ city

Clayton

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain

Revenue model

1. Nuclear Medicine Production and Sales: Production and commercial sale of radiopharmaceuticals and radiochemicals for medical diagnostics and therapy
2. Research Services: Providing access to nuclear science facilities, instruments, and expertise for external researchers and industry clients on a fee-for-service basis
3. Analytical Services: Commercial analytical testing services for resources sector, environmental monitoring, and industrial clients including minerals processing and chemical analysis
4. Radiation Services: Radiation safety training, consultancy services, and instrument calibration for external clients
5. Education and Training: Graduate programs, internships, tours, and educational workshops generating revenue and building nuclear science workforce
6. Government Funding: Core operational funding from Australian Government as statutory authority, supplemented by commercial activities

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Core offering

ANSTO operates Australia's national nuclear science and technology research infrastructure, providing production and supply of radiopharmaceuticals and radiochemicals for nuclear medicine, access to specialised research facilities including the OPAL multi-purpose reactor, the Australian Synchrotron, the Centre for Accelerator Science, and the National Deuteration Facility, alongside commercial minerals processing testwork, radiation safety services, nuclear waste management via ANSTO Synroc, and irradiation and advanced manufacturing services for industry clients.

Product overview

ANSTO is Australia's national nuclear science organization operating as a multi-facility research infrastructure platform. The core offerings include the OPAL multi-purpose research reactor for radioisotope production, the Australian Synchrotron in Melbourne for advanced beamline research, and the Australian Centre for Neutron Scattering. Products include Nuclear Medicine (radiopharmaceuticals and radiochemicals), ANSTO Synroc (waste immobilization technology), and CORIS360 detection/imaging systems. Services span minerals processing, radiation safety, waste solutions, advanced manufacturing, and irradiation services. The organization provides research access to external scientists through dedicated user portals at both Sydney and Melbourne facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Nuclear Medicine Production and commercial supply of radiopharmaceuticals, radiochemicals, and nuclear medicine accessories for medical diagnosis and treatment applications, delivered to hospitals and healthcare providers in Australia and exported internationally.
• ANSTO Synroc Advanced nuclear waste immobilisation technology using Synroc synthetic rock for the safe containment and treatment of radioactive waste from nuclear operations.
• CORIS360 Detection and Imaging Gamma neutron imaging systems and radiation detection solutions using CORIS360 compressed sensing technology for industrial and security applications.
• OPAL Multi-Purpose Reactor Services Research nuclear reactor providing neutron irradiation, neutron activation analysis, and production of radioisotopes for medical and research applications, accessed by external researchers and industry clients on a fee-for-service basis.
• Australian Centre for Neutron Scattering Services Neutron scattering instruments and user access facility including the Quokka instrument for materials science research, with industry access at Lucas Heights and dedicated user portal for proposal-based beamtime allocation.
• Australian Synchrotron Beamline Services Synchrotron radiation facility with multiple beamlines for crystallography (MX1, MX2, MX3), imaging, and materials characterisation research, with commercial services and Proposal Advisory Committee access processes in Clayton, Melbourne.
• Centre for Accelerator Science Services Accelerator mass spectrometry facility providing radiocarbon dating, isotopic analysis, and trace element detection services supporting archaeological and environmental research, accessed via a dedicated user portal.
• National Deuteration Facility Services Biodeuteration and chemical deuteration services producing deuterium-labelled compounds that support neutron scattering research and other scientific applications, accessed through a dedicated user access process.
• Minerals Processing Services Technical support for mineral processing including crushing, milling, screening, and pilot-scale testing for uranium and critical minerals extraction, provided to mining companies, mineral processing firms, and rare earth developers.
• Radiation Services Radiation safety training, instrument calibration, and consultancy services for industrial and commercial radiation applications.
• Waste Solutions Nuclear waste management services including treatment, characterisation, and disposal for clients requiring safe handling of radioactive materials.
• Advanced Manufacturing Services Hot isostatic pressing (HIPing) and materials characterisation services for advanced manufacturing customers requiring high-performance materials processing.
• Irradiation Services Silicon irradiation for semiconductor doping and gamma irradiation services for medical device sterilisation and materials testing, provided to industrial and medical clients.
• Space Radiation Testing Radiation testing services for materials and electronic devices to assess performance and resilience in space radiation environments, supporting aerospace and defence customers.
• Discovery Centre Tours Educational tours and STEM workshops delivered to schools and the public at the Lucas Heights Discovery Centre to support nuclear science workforce and community engagement.
• Clay Rare Earth Processing Services Pilot-scale processing of ion-adsorption clay rare earth deposits using hydrometallurgical methods, supported by over $3 billion in Australia-US financing, with Australian Rare Earths' Koppamurra project as the primary user.

Quantifiable outcome

• Australia's first clay rare earth processing facility scheduled for commissioning in 2026
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• OECD Nuclear Energy AgencycoreStrategic or Co-development Partner · 6 July 2026Co-organising the first Asia-Pacific Workshop on Medical Radioisotopes with the OECD NEA, scheduled for 6-7 July 2026 at UNSW Sydney. The workshop will address supply chain challenges and explore opportunities in therapeutic radioisotopes including Lu-177 and Ac-225, convening nuclear-related organisations, regulators, radio pharmacists, industry stakeholders, and government policymakers.
• University of New South WalescoreStrategic or Co-development PartnerHost venue partner for the Asia-Pacific Workshop on Medical Radioisotopes co-organised with OECD NEA, taking place 6-7 July 2026 at UNSW Sydney campus.
• Chilwa MineralsminorStrategic or Co-development PartnerASX-listed mining company commissioning ANSTO in Sydney to conduct ammonium-sulphate leach testing on rare earth samples from Mposa deposit in Malawi to determine ionic-adsorption clay form of rare earths for economic evaluation.
• Critica LimitedcoreStrategic or Co-development PartnerAustralian rare earths company partnered with ANSTO for metallurgical testwork at Jupiter clay-hosted rare earth project in Western Australia. ANSTO confirmed production of first high-quality mixed rare earth carbonate grading 58% TREO using conventional sulphuric acid bake process.
• Australian Rare EarthscoreStrategic or Co-development PartnerAustralian Rare Earths' Koppamurra project designated as primary user of ANSTO's first clay rare earth processing facility scheduled for commissioning in 2026, targeting strategic supply chain vulnerabilities created by China's approximately 85% share of global rare earth processing capacity.
• Design Factory Melbourne (Swinburne University)coreStrategic or Co-development PartnerPartnership between ANSTO's nandin Innovation Centre and Swinburne University's Design Factory Melbourne for a three-year full-time PhD scholarship program in innovation, design and technology based at Lucas Heights, Sydney.
• Australian Institute of Nuclear Science and Engineering (AINSE)coreStrategic or Co-development PartnerANSTO collaborates with AINSE to offer Residential Student Scholarships and SAAFE (Scholarship AINSE ANSTO French Embassies) Program supporting early career researchers in nuclear science and engineering for exchanges between Australia/New Zealand and France.
• French EmbassiesminorStrategic or Co-development PartnerSAAFE Program partnership with French Embassies providing travel funding and accommodation support for PhD and postdoctoral researchers to conduct collaborative nuclear science research between France and Australia/New Zealand.
• University of Western AustraliacoreStrategic or Co-development PartnerMulti-disciplinary research collaboration on Barrow Island Archaeology Project led by UWA, with ANSTO's Centre for Accelerator Science providing radiocarbon and optical luminescent dating for evidence of earliest Aboriginal occupation of Australian coast dating back 46,200-51,100 years.
• Kimberley Foundation AustraliacoreStrategic or Co-development PartnerFunding and research collaboration on Kimberley Rock Art Dating Project, with ANSTO scientists contributing accelerator mass spectrometry for cosmogenic radionuclide measurements and radiocarbon dating supporting rock art chronology spanning up to 50,000 years.
• Flinders UniversityminorStrategic or Co-development PartnerResearch collaboration where Flinders University investigators used ANSTO facilities to reveal molecular cage technology to trap PFAS forever chemicals, providing a remediation pathway.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Atomic Energy of Canada Limited (AECL): Canadian Government nuclear research organization that operates national nuclear science infrastructure and supports isotope production and reactor-based research. Most analogous national nuclear lab structure to ANSTO with similar mandate to operate research reactors on behalf of a national government.
• Nordion: Canadian medical isotope producer historically supplying Co-60 and Mo-99 from AECL reactors. Directly comparable to ANSTO's nuclear medicine production activity using research-grade reactor infrastructure.
• Curium Pharma: Global nuclear medicine company producing radiopharmaceuticals and radiochemicals for SPECT and PET imaging and therapy. Closest commercial peer to ANSTO's nuclear medicine products and services.
• Lantheus Holdings: Radiopharmaceutical-focused company developing and commercializing diagnostic and therapeutic agents including Lu-177-based products. Comparable product portfolio (radiopharmaceuticals) and target therapeutic isotopes including those produced by ANSTO's OPAL reactor.
• IBA (Ion Beam Applications): Belgian company operating across radiopharma solutions, proton therapy, and particle accelerators. Comparable to ANSTO across radioisotope production technology (cyclotron-based) and accelerator science facility operations.
• Paul Scherrer Institute (PSI): Swiss national research institute operating accelerator facilities, a synchrotron (Swiss Light Source), and research reactor capabilities. Direct analog to ANSTO's combination of synchrotron, neutron scattering, and accelerator mass spectrometry infrastructure.
• Institut Laue-Langevin (ILL): French-European operator of the leading continuous neutron source for research, offering beamtime to international scientific users. Comparable to ANSTO's Australian Centre for Neutron Scattering in mission and user-access model.
• UK Atomic Energy Authority (UKAEA): UK Government nuclear research organization focused on fusion energy and advanced materials. Comparable structurally as a statutory national nuclear research body addressing strategic clean-energy priorities, similar to ANSTO's nuclear stewardship role for Australia.
• Oak Ridge National Laboratory: US Department of Energy national laboratory operating the High Flux Isotope Reactor and Spallation Neutron Source, conducting isotope production and neutron research. Direct analog to ANSTO's OPAL-driven research and isotope production functions.

Regional players

• Lynas Rare Earths: Australian-listed rare earth miner and the largest non-Chinese producer of separated rare earth oxides. Comparable Australian rare earth processing ambitions and dependency on critical mineral supply chain strategy, though commercial-scale rather than research-and-pilot focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ansto
• YouTubeyoutube.com/user/ANSTOVideos
• Facebookfacebook.com/discoveransto
• LinkedInlinkedin.com/company/ansto
• Instagraminstagram.com/ansto

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australian Nuclear Science and Technology Organization